• The Future Of Highly Potent API Manufacturing - Lonza Perspective

    Highly potent active pharmaceutical ingredients (HPAPIs) represent an increasing fraction of new compounds in pharmaceutical pipelines today. Flexible and phase-appropriate infrastructure is needed to bring the next innovative medicines based on these challenging compounds from concept to commercialization. Thispresentation describes Lonza's HPAPI "manufacturing 4.0" investments and the company's innovative capabilities.

  • Telltale Signs You’re With The Wrong CDMO

    Is your CDMO an asset or a hindrance? This article explores 10 red flags that signal your parter isn't carrying its weight on your journey to commercialization.

  • Continuous Or Batch: Deciding On The Best Solution For Your Oral Solid Dose Product

    Gaining a better understanding of continuous manufacturing and its fitness for your OSD product could secure more control over the quality and safety of your product and, ultimately, the future of its success.

  • Outsourcing Success Requires Constant Evolution

    Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.


  • Enviero™ Progesterone: Green Chemistry Progesterone API

    Enviero progesterone is the first compound launched from Pfizer CentreOne’s Enviero green-chemistry program and is being adopted across Pfizer providing the latest in lower environmental impact products for patients around the world. Download our brochure to learn more.

  • Light Path™ Custom Material Supply: Mammalian And Microbial Custom Services For Protein Production

    At Lonza, we understand the challenges facing biotherapeutic and vaccine manufacturers related to the time and costs inherent in the drug discovery and development process. Light Path™ Custom Material Supply Services are efficient, focused technology and production offerings for the Preclinical and Phase I stages of novel biologics development.

  • Container Closure Integrity Testing

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Accelerating Product Development With Intelligent Collaboration

    Pfizer CentreOne is a global CDMO embedded within Pfizer and has a global network ready to deliver end-to-end analytical and manufacturing expertise. Collaborating with you, we can help take your molecule all the way from proof of concept through commercial launch and lifecycle management.

  • Better Treatments By Design: Optimal Dose Development And Manufacturing

    To be successful, new treatments require superior real world outcomes providing market differentiation and delivering the best outcomes to you, your stakeholders, and most importantly the patients who depend on your therapy. With the Better Treatments by Design™ process, Catalent aims to achieve optimal outcomes for innovators, prescribers, and patients.